Skip to main content
. 2022 Feb;10(4):214. doi: 10.21037/atm-22-358

Figure 3.

Figure 3

TMB and cancer-associated mutations in blood samples. (A) TMB among KRAS p.G12A (n=1), p.G12C (n=3), p.G12D (n=9), p.G12R (n=5), p.G12V (n=11), and KRAS other (n=467) alterations in blood samples. (B) TMB between KRAS other (n=467) alterations and KRAS p.G12 (n=29) alteration. (C) TMB between EGFR mutation-negative patients (n=484) and EGFR mutation-positive patients (n=12) in blood samples. (D) TMB in blood samples between EGFR T790M mutation-negative patients and EGFR T790M mutation-positive patients. TMB, tumor mutational burden; KRAS, Kirsten rat sarcoma; EGFR, epidermal growth factor receptor.